Product Introduction
Bioactivity


英文名: ML224

描述: ML224 (NCGC00242364) 是一种具有选择性和有效性的 TSHR 拮抗剂，可用于治疗 Graves 眼眶病、Graves 甲状腺功能亢进症和/或甲状腺癌。

体外活性: In human embryonic kidney 293 cells, ML224 exhibits a half-maximal inhibitory concentration (IC50) of 2.1 μM against TSHR after a 20-minute exposure, with a range of 0.001-100 μM. The half-maximal inhibitory concentrations against LH and FSH receptors exceed 30 μM[1].

体内活性: ML224(ANTAG3)每只小鼠2毫克，通过腹腔内输液泵每日一次连续给药3天，能够降低长期TRH刺激小鼠的血清FT4水平及甲状腺TPO和NIS的mRNA水平[1]。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 80 mg/mL (152.21 mM)


关键字: NCGC 00242364 | ML 224 | ANTAG-3 | ANTAG 3 | NCGC-00242364 | ML224 | ML-224

相关产品: D3-βArr | ML-109 | TSHR antagonist S37 | Org41841 | NCGC00229600 | VA-K-14 hydrochloride | Teprotumumab

相关库: Membrane Protein-targeted Compound Library | GPCR Compound Library